Neutrophil Phenotypic Profiling and Organ Injury Assessment in Patients With Sepsis
NCT ID: NCT04103268
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
72 participants
OBSERVATIONAL
2020-08-04
2026-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Expression Profiles of Integrin αDβ2 on Neutrophils in Sepsis
NCT04103281
Dissecting How Peripheral Lymphocytes Are Lost During Sepsis
NCT03289312
Novel Sepsis Sub-phenotypes Based on Trajectories of Vital Signs
NCT05826223
A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children
NCT05142813
Algorithm for Predicting the Unfavorable Course of Sepsis in Children
NCT05908162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sepsis
sepsis
patients in the ICU with infection called sepsis
Control
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sepsis
patients in the ICU with infection called sepsis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meet the definition of sepsis described in the study design section above. Patients will be eligible for enrollment as control patients if they
* Are \< 18 years old
* Are scheduled for an elective surgical procedure and need preoperative blood draw or will have an intravenous catheter placed for the purpose of their surgical procedure.
Exclusion Criteria
* On chronic immunosuppressive drugs such as chronic corticosteroid use, or preexisting immunodeficiency diseases
1 Month
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Koichi Yuki
Cardiac Anesthesiologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Koichi Yuki, MD
Role: PRINCIPAL_INVESTIGATOR
Boston Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boston Children's Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Alhamdan F, Gianoli S, Yuki K, Koutsogiannaki S. Single-cell analysis of B cell dysregulation in pediatric sepsis stratified by disease severity. Sci Rep. 2025 Dec 31. doi: 10.1038/s41598-025-34126-9. Online ahead of print.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-P00031930
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.